Skip to main content

COVID-19

RheumNow Podcast square

Telemedicine Upside Interview with Dr. Alvin Wells

Dec 03, 2021

In spite of the transformative growth of telemedicine during the COVID-19 pandemic, rheumatologists use of telemedicine is waning, much like the use of masks. Dr. Jack Cush interviews telemedicine guru, Dr. Alvin Wells, on the current state of telemedicine and what the future holds for

Read Article
ICYMI: Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLEhttps://t.co/ihWapOaiNO https://t.co/daoIZtpsHH
Dr. John Cush @RheumNow( View Tweet )
Nov 28, 2021
COVID-19 in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica Dr. Bella Mehta ( @bella_mehta) interviews Dr. Sebastian Sattui about abstract #0952 presented at the #ACR21 annual meeting.https://t.co/BYyz0Xj1Fj

Dr. John Cush @RheumNow( View Tweet )

Nov 24, 2021
COVID-19 Vaccination in Autoimmune Disease: Dr. Sheila Reyes ( @RHEUMarampa) interviews Dr. Latika Gupta about abstract #0444, presented at the #ACR21 annual meeting.https://t.co/yFqj3fAtrW https://t.co/idWis7FURI
Dr. John Cush @RheumNow( View Tweet )
Nov 22, 2021
covid vaccine needle vaccination

Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE

It is almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under emergency use authorization (EUA). The question still being asked is whether the vaccine is safe for people with lupus? 



It is worth noting that the Phase III randomised

Read Article
covid coronavirus virus

More severe COVID-19 outcomes in African American, Hispanic individuals with SLE

A study from ACR21 convergence discussing data from the Global Rheumatology Alliance (GRA) describes the association between race/ethnicity on COVID-19 outcomes specifically in lupus patients.

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
iv.infusion.jpg

Can "Ultra-low" dose Rituximab work for RA?

Nov 11, 2021

The REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis. Their study randomized 118 patients with rheumatoid arthritis to 1000 mg, 500 mg, and "ultra-low" dose 200 mg.

Read Article
audience learn

Day 4 Report from ACR21

Nov 10, 2021

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article
Love this COVID ARDS risk calculator put forth by @JYazdanyMD at #ACR21 for our patient's with Rheumatic Diseases. A wonderful resource in talking to our patients about vaccine necessity! @CleClinicMD https://t.co/EA5jVYweHm
Emily Littlejohn @ELittlejohnDO( View Tweet )
Nov 09, 2021
#ACR21 Late breaking #ACRambassador Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled EMR Data Repository https://t.co/oyovR27Upm

Marie Kuchynski MD @Doctorkuch( View Tweet )

Nov 09, 2021
Reasons for COVID-19 vaccine hesitancy in rheumatology pts in southeast US based on survey study: 🔰Vaccine being “rushed” or “experimental” 🔰Safety of vaccine in the patients’ rheumatologic diagnoses 🔰Side effects 🔰Concern for Allergic reaction Abst#1589 #ACR21 @RheumNow https://t.co/xm15KxdA56
swethaann23 @swethaann23( View Tweet )
Nov 09, 2021
Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting.https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke
Dr. John Cush @RheumNow( View Tweet )
Nov 09, 2021
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof) It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus?https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T
Dr. John Cush @RheumNow( View Tweet )
Nov 09, 2021
EULAR19.abstract.jpg (keep)

ACR21 – Day 3 Report

Nov 09, 2021

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Read Article
GRA @rheum_covid data presented by @mugartegil. African-American and Hispanic individuals with SLE have MUCH worse COVID-19 outcomes. Likely related socioeconomic and health disparities. Abstr#1933 #ACR21 @RheumNow https://t.co/YUoOeIxN7O
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
🚫Infection risk after COVID vaccination: US database 536 954 Controls and 47 303 pts w/ RMDs 〽️BNT162b2 19 vs. 36/1000 〽️ mRNA-1273 16 vs. 33/1000 〽️Janssen 26 vs. 47/1000 Infections ⬆️ RA, SpA, SLE, SSc, Polymyositis #ACR21 #AbstL16 @RheumNowhttps://t.co/xzOaFIu06e@RheumNow https://t.co/tmr4USETJ3
Aurelie Najm @AurelieRheumo( View Tweet )
Nov 09, 2021
#ACR21 #AbstrL17 In pts treated with Rituximab, arrange a 3rd primary dose ASAP regardless mRNA or vector #COVID vaccine. An RCT of N=60 pts who did not seroconvert after primary dose, overall 94% either seroconverted/new T-cell response @RheumNow #ACRBest https://t.co/F15j93OFE4 https://t.co/tXoisoYthx
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 09, 2021
CH COVID 19 Poster Review Abst 0196 Jackson & colleagues performed double blind RCT of anakinra in patients with features of COVID-19 cytokine storm - Anakinra + GC did not significantly impact outcomes in patients with cytokine storm syndrome #ACR21 @RheumNow https://t.co/hX7bBtrIzT
Akhil Sood MD @AkhilSoodMD( View Tweet )
Nov 09, 2021
Late breaking, but just in time! mRNA COVID-19 3rd dose in RTX pts, w/o Ab response post initial series. After 3rd dose many had ab response or T cell response. Extra vaccine full doses can protect RTX pts from COVID! AbsL17 #ACRbest #ACR21 @RheumNow https://t.co/lIDPzybmT7 https://t.co/jEJ3N6cdjK
Dr. Rachel Tate @uptoTate( View Tweet )
Nov 09, 2021
Complications of Covid19 in Lupus: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #1933 presented at the #ACR21 annual meeting.https://t.co/jKFJwCBeCo https://t.co/ncleyYZWLn
Dr. John Cush @RheumNow( View Tweet )
Nov 09, 2021
#ACR21 L17: Heterologous vs Homologous Booster vax ▶️RTX non-responders to mRNA: Randomized to mRNA 3rd dose vs AZ vax ⭐️Majority of pts develop immune response (humoral and/or cellular) after 3rd dose, no statistical diff b/w groups @Rheumnow https://t.co/cuM9LcEr4u https://t.co/cmNBNSIoOl
Nov 09, 2021
What to do w Rituximab users and #COVID19 vaccine? #Rituximab no seroconversion 30% with 2 #COVIDVaccination. With 3rd vaccine dose up to 94% can have immune response! Pts need their 3rd vaccination @RheumNow #ACR21 #ACRBest abstL17 https://t.co/0GHOuoqPKQ
Nov 09, 2021
👉29% of pts on RTX fail to mount a humoral OR cellular response to #COVIDvaccine & have⬆️hosp,⬆️hosp stay,⬆️severity, persistent viremia,⬆️deaths) 👉study adding booster (AZ or mRNA) overcomes this, enhancing humoral and cellular response #ACR21 @rheumnow Abst#L17 https://t.co/yuX1TT6ZBF
TheDaoIndex @KDAO2011( View Tweet )
Nov 09, 2021
Very interesting talk Abst L16 Singh & colleagues found that patients with rheumatic diseases are at increased risk for breakthrough infxn - Recent drug exposure and certain medication type can influence outcomes - Findings support need for 3rd dose in RD pts #ACR21 @RheumNow https://t.co/vU6ZNIEWbc
Akhil Sood MD @AkhilSoodMD( View Tweet )
Nov 09, 2021
×